Showing results (1-10 of 52) with videos related to
Sort By:
Pageof 6
Pharmaceutical Statistics|June 16, 2020
A Bayesian approach in design and analysis of pediatric cancer clinical trialsJingjing Ye, Gregory Reaman, R Angelo De Claro, et al.Therapeutic Innovation & Regulatory Science|September 19, 2018
Dose Finding in Late-Phase Drug DevelopmentLei Nie, Kyung Y Lee, Nicole Verdun, et al.The Oncologist|April 26, 2017
FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin LymphomaYvette L Kasamon, R Angelo de Claro, Yaping Wang, et al.Nature Communications|July 27, 2022
Decoding kinase-adverse event associations for small molecule kinase inhibitorsXiajing Gong, Meng Hu, Jinzhong Liu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review ProgramR Angelo de Claro, Jennifer J Gao, Tamy Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2025
FDA Approval Summary: Blinatumomab for the Treatment of B-cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase ChemotherapyCara A Rabik, Shu Wang, Ritu Chadda, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2019
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary SyndromeYvette L Kasamon, Haiyan Chen, R Angelo de Claro, et al.Blood|May 10, 2024
Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemiaRobert Q Le, Donna Przepiorka, Haiyan Chen, et al.The Oncologist|March 28, 2019
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell LymphomaNicholas C Richardson, Yvette L Kasamon, Haiyan Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2026
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall SurvivalElizabeth S Duke, Diana Bradford, Arup K Sinha, et al.Pageof 6